Subsequently, the FDA approved nivolumab (3 mg/kg) combined with ipilimumab (1 mg/kg) for first-line use in advanced NSCLC with PD-L1 ≥ 1%. This evidence concerns the gene CD274 and non-small cell lung carcinoma.